Head-To-Head Analysis: Hikma Pharmaceuticals (OTCMKTS:HKMPF) vs. ProPhase Labs (NASDAQ:PRPH)

ProPhase Labs (NASDAQ:PRPH) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Risk & Volatility

ProPhase Labs has a beta of -0.56, suggesting that its share price is 156% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.

Institutional and Insider Ownership

9.5% of ProPhase Labs shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for ProPhase Labs and Hikma Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1	0	0	0	1.00
Hikma Pharmaceuticals	0	0	1	0	3.00

Valuation and Earnings

This table compares ProPhase Labs and Hikma Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$6.77 million	0.25	-$53.36 million	($3.90)	-0.09
Hikma Pharmaceuticals	$3.13 billion	1.49	$359.00 million	N/A	N/A

Hikma Pharmaceuticals has higher revenue and earnings than ProPhase Labs.

Profitability

This table compares ProPhase Labs and Hikma Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Hikma Pharmaceuticals	N/A	N/A	N/A

Summary

Hikma Pharmaceuticals beats ProPhase Labs on 9 of the 11 factors compared between the two stocks.

About ProPhase Labs

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.